MXPA04001388A - Expandable gastric retention device. - Google Patents

Expandable gastric retention device.

Info

Publication number
MXPA04001388A
MXPA04001388A MXPA04001388A MXPA04001388A MXPA04001388A MX PA04001388 A MXPA04001388 A MX PA04001388A MX PA04001388 A MXPA04001388 A MX PA04001388A MX PA04001388 A MXPA04001388 A MX PA04001388A MX PA04001388 A MXPA04001388 A MX PA04001388A
Authority
MX
Mexico
Prior art keywords
gastric retention
retention device
expandable gastric
expandable
therapeutics
Prior art date
Application number
MXPA04001388A
Other languages
Spanish (es)
Inventor
W Ayres James
Original Assignee
Oregon State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State filed Critical Oregon State
Publication of MXPA04001388A publication Critical patent/MXPA04001388A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0419—Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present application concerns gastric retention devices formed from compositions comprising polymeric materials, such as polysaccharides, and optional additional materials including excipients, therapeutics, and diagnostics, that reside in the stomach for a controlled and prolonged period of time.
MXPA04001388A 2001-08-16 2001-10-22 Expandable gastric retention device. MXPA04001388A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31307801P 2001-08-16 2001-08-16
PCT/US2001/046146 WO2003015745A1 (en) 2001-08-16 2001-10-22 Expandable gastric retention device

Publications (1)

Publication Number Publication Date
MXPA04001388A true MXPA04001388A (en) 2004-05-27

Family

ID=23214285

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001388A MXPA04001388A (en) 2001-08-16 2001-10-22 Expandable gastric retention device.

Country Status (14)

Country Link
EP (1) EP1416914A1 (en)
JP (1) JP2005501097A (en)
KR (1) KR20040032918A (en)
CN (1) CN1543337A (en)
BR (1) BR0117123A (en)
CA (1) CA2456976A1 (en)
CO (1) CO5670360A2 (en)
IL (1) IL160363A0 (en)
MX (1) MXPA04001388A (en)
NO (1) NO20040611L (en)
NZ (1) NZ531461A (en)
PL (1) PL368327A1 (en)
WO (1) WO2003015745A1 (en)
ZA (1) ZA200402066B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427391B2 (en) * 2001-11-21 2008-09-23 E-Z-Em, Inc. Formulations for use in medical and diagnostic procedures
WO2005062898A2 (en) * 2003-12-24 2005-07-14 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
US7699863B2 (en) 2005-03-01 2010-04-20 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
US7785291B2 (en) 2005-03-01 2010-08-31 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
EP2046397A2 (en) * 2006-07-19 2009-04-15 SmithKline Beecham Corporation Method for radiolabeling formulations for gamma scintigraphy assesment
CN102552103B (en) * 2010-12-20 2013-11-20 西安力邦医药科技有限责任公司 Lamivudine solid dispersion, and preparation method, pharmaceutical composition and use of the dispersion
CN104334123B (en) 2012-06-07 2019-02-12 意比图密医疗有限公司 Expansion device
WO2015083171A1 (en) 2013-12-05 2015-06-11 Tulip Medical Ltd. Retentive devices and systems for in-situ release of pharmaceutical active agents
ES2832334T3 (en) 2014-06-11 2021-06-10 Massachusetts Inst Technology Permanence structures and related methods
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
EP3288604B1 (en) 2015-05-01 2021-11-17 Massachusetts Institute of Technology Triggerable shape memory induction devices
WO2017070612A1 (en) 2015-10-23 2017-04-27 Lyndra, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
KR20180090881A (en) 2015-12-08 2018-08-13 린드라 인코퍼레이티드 Geometric configuration for the above stay system
CA3038557A1 (en) 2016-09-30 2018-04-05 Lyndra, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
WO2019126218A1 (en) * 2017-12-18 2019-06-27 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
TR201914116A2 (en) * 2019-09-17 2021-04-21 Univ Yeditepe PRODUCTION METHOD OF NATURAL BIOMATERIALS AND CRYOGELS AND THE USE OF THESE CRYOGELS AS SOFT TISSUE SCACHE OR DRUG CARRIER SYSTEM
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764380A (en) * 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
DE4406424A1 (en) * 1994-02-28 1995-08-31 Bayer Ag Expandable dosage forms
EP1003476B1 (en) * 1997-08-11 2004-12-22 ALZA Corporation Prolonged release active agent dosage form adapted for gastric retention
NZ510487A (en) * 1998-09-14 2003-04-29 Ranbaxy Lab Ltd Pharmaceutical composition comprising ciprofloxacin, sodium alginate, xanthan gum and a cross-linker polymer in a tablet or capsule form
JP2000256216A (en) * 1999-03-04 2000-09-19 Meiji Milk Prod Co Ltd Gel composition
AU2001268722B8 (en) * 2000-06-23 2005-09-29 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Also Published As

Publication number Publication date
ZA200402066B (en) 2005-05-09
NO20040611L (en) 2004-04-16
PL368327A1 (en) 2005-03-21
CA2456976A1 (en) 2003-02-27
CN1543337A (en) 2004-11-03
NZ531461A (en) 2008-03-28
EP1416914A1 (en) 2004-05-12
WO2003015745A1 (en) 2003-02-27
CO5670360A2 (en) 2006-08-31
KR20040032918A (en) 2004-04-17
BR0117123A (en) 2004-09-28
IL160363A0 (en) 2004-07-25
JP2005501097A (en) 2005-01-13

Similar Documents

Publication Publication Date Title
WO2005079384A3 (en) Expandable gastric retention device
MXPA04001388A (en) Expandable gastric retention device.
MXPA03003515A (en) Rheology modifying copolymer composition.
IL144147A0 (en) Regulators of the pct or smoothened pathway, compositions and uses related thereto
MXPA02008398A (en) High early-strength cementitious composition.
AU6872201A (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
MXPA03002070A (en) Contraception process and administration form for the same.
ZA200003997B (en) Pharmaceutical compositions.
IL171875A0 (en) Pioglitazone salts,such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
AP1703A (en) Heparin-derived polysaccharide mixtures, preparation method and pharmaceutical compositions containing same.
DE602004025338D1 (en) POLYMERIZABLE COMPOUND, COPOLYMERS, COMPOSITION THEREIN, PICTURE PRODUCTION METHOD AND IMAGE GENERATING DEVICE
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
RS97604A (en) New etonogestrel esters
ZA200206779B (en) Solid formulation.
MXPA03000624A (en) Compositions and films for capsule manufacture.
MXPA03002105A (en) Pharmaceutical compositions.
IL157065A0 (en) 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
AU2002212895A1 (en) N-type calcium channel antagonists for the treatment of pain
HUP0302208A3 (en) Deltamethrin-containing, water-dispersible granular material, production and use thereof
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
GB0118368D0 (en) Light-emmisive polymer blends and light-emissive devices made from the same
AU2002210491A1 (en) Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof
HUP0204422A3 (en) Calcium dicarboxylate ethers, methods of making the compounds, and pharmaceutical compositions containing them
GB0428306D0 (en) Compound
HK1038515A1 (en) Controlled delivery of antidepressants

Legal Events

Date Code Title Description
FA Abandonment or withdrawal